This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B22.1 (HIV disease resulting in lymphoid interstitial pneumonitis) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | Lymphoid interstitial pneumonia (LIP); Lymphoid interstitial pneumonitis; HIV-associated LIP; Pulmonary lymphoid hyperplasia (PLH) |
| C. Adult onset | Likelihood of adult onset: low to moderate — HIV-associated lymphoid interstitial pneumonia (LIP) occurs more commonly in HIV-infected children. It is relatively uncommon in HIV-infected adults, but can occur in the chronic stage of HIV infection with partially preserved CD4+ T-cell counts, and some cases are associated with Sjögren's syndrome or EBV reactivation. |
| 1. History | LIP first described as an AIDS-defining illness in HIV-infected children in 1987. Pediatric AIDS-defining criterion in the 1987 CDC classification. Rare in adults, but recognized as an important differential diagnosis of chronic interstitial lung disease. |
| 2. Causes | Immune dysregulation by HIV. EBV (Epstein-Barr virus) co-infection. Accumulation of alveolar lymphocytes driven by the HIV gp120 protein. Abnormal pulmonary immune response led by CD8+ T lymphocytes. |
| 3. Genetics | Not a hereditary disease. EBV viral genes (LMP-1, EBER) induce lymphocyte proliferation. HLA type influences EBV reactivation and the immune response. |
| 4. General epidemiology | Occurs in about 25–40% of HIV-infected children. Uncommon in adults, at 1–3% of all HIV-infected individuals. Incidence has fallen markedly since ART. Still relatively common in African children with HIV. |
| 5. Pathophysiology | HIV infection → abnormal accumulation of alveolar lymphocytes (mainly CD8+ T cells) → lymphocytic infiltration of the alveolar interstitium and peribronchiolar areas → impaired gas exchange. EBV co-infection further promotes lymphoproliferation. |
| 6. Symptoms | Chronic cough (nonproductive), progressive dyspnea, exertional hypoxemia. In children, accompanied by clubbing, parotid swelling, and lymphadenopathy. Fever occurs intermittently. |
| 7. Signs | Chest X-ray: bilateral interstitial infiltrates, lower-lobe predominant. HRCT: bilateral nodules (peribronchial/perivascular), ground-glass opacity, cysts. Pulmonary function: restrictive ventilatory defect, decreased DLCO. Lung biopsy: interstitial infiltration with CD8+ lymphocyte predominance. |
| 8. Screening | Chest X-ray and HRCT in HIV-infected children and adults with respiratory symptoms. Assess hypoxemia by pulse oximetry. Include EBV serology. |
| 9. Diagnosis | Definitive diagnosis: histopathology of bronchoalveolar lavage fluid (BAL) or surgical lung biopsy. HRCT findings (bilateral nodules, ground-glass opacity, cysts) are characteristic. EBV role confirmed by EBV EBER in situ hybridization. Differentiation from lymphoma is essential. |
| 10. Treatment | ART initiation first. If hypoxemia is present (PaO₂ <60 mmHg), add corticosteroids (prednisolone 1 mg/kg/day). If symptoms are mild, improvement with ART alone. Add steroids if worsening due to IRIS. |
| 11. Prognosis | Mostly stabilizes or improves after ART. Five-year survival in children about 60–80%. Pneumothorax risk when cysts form. Rarely progresses to lymphoma. In adults, prognosis depends on ART adherence and baseline CD4 count. |
| 12. Prevention | Early HIV diagnosis and early ART initiation prevent LIP. Regular pulmonary function monitoring in HIV-infected children. Manage EBV co-infection. |
| 13. References | Includes 10 key references |
Lymphoid interstitial pneumonia (LIP) was first described in 1966 by Liebow and Carrington as an independent lung disease with extensive infiltration of lymphocytes and plasma cells in the pulmonary interstitium. Initially, associations with autoimmune diseases, Sjögren's syndrome, and other connective tissue diseases were mainly reported.
After the HIV/AIDS epidemic, LIP was re-examined in a new context. In 1987 the US Centers for Disease Control and Prevention (CDC) officially included LIP as an AIDS-defining illness in HIV-infected children. This reflected the recognition that LIP holds an important place as an opportunistic lung disease in HIV-infected children. In the CDC classification criteria of the time (1987), LIP was defined as bilateral interstitial infiltrates on chest X-ray with lymphoproliferative histologic findings in an HIV-infected child, or persistence for 3 months or more.
In the 1990s, Epstein-Barr virus (EBV) was found to be an important co-factor in the pathogenesis of LIP. EBV EBER (EBV-encoded RNA) in situ hybridization in lung tissue confirmed that EBV promotes lymphocyte proliferation in many HIV-associated LIP patients. This established that the combined action of HIV and EBV is central to the pathogenesis of LIP.
Since the introduction of ART in 1996, the incidence of LIP has fallen markedly in both children and adults. Immune recovery by ART was understood to suppress the occurrence of LIP by correcting HIV-associated pulmonary immune abnormalities. However, in some patients transient worsening of LIP due to immune reconstitution inflammatory syndrome (IRIS) was also observed early after ART initiation.
At present, HIV-associated LIP is rare in adults and occurs mainly in African children with HIV or children not treated with ART. In high-income countries, LIP is classified as a rare complication owing to the spread of ART, but in low-income countries it remains an important public health problem.
The cause of HIV-associated lymphoid interstitial pneumonia (LIP) is explained by the interaction of pulmonary immune dysregulation from HIV infection and EBV co-infection.
Direct effects of HIV: HIV infects alveolar macrophages and T lymphocytes, disturbing the local immune environment of the lung. The HIV gp120 protein binds to the CXCR4 receptor and promotes abnormal migration of CD8+ T lymphocytes into lung tissue. In addition, the HIV Tat protein induces secretion of various inflammatory cytokines (IL-6, TNF-α, IL-10) from lung epithelial cells and immune cells, promoting lymphocyte proliferation and interstitial infiltration of the lung.
EBV co-infection: EBV infects B lymphocytes and converts them to a state of perpetual proliferation. Reduced cellular immunity from HIV infection permits EBV reactivation, and EBV-infected B cells accumulate in the lung interstitium. The EBV latent membrane protein LMP-1 inhibits apoptosis of B cells and promotes their proliferation. In LIP lung tissue, EBV EBER is extensively expressed in CD20+ B lymphocytes and plasma cells.
CD8+ T-cell immune hyperreaction: in HIV-infected individuals, CD8+ T cells are abnormally activated by chronic antigenic stimulation. These activated CD8+ T cells infiltrate the lung interstitium and cause inflammation. Most (60–80%) of the cells infiltrating lung tissue are CD8+ T lymphocytes.
Autoimmune mechanism: antinuclear antibodies (ANA), rheumatoid factor, and anti-Ro/La antibodies are detected in some patients with HIV-associated LIP. This suggests that autoimmune phenomena due to HIV immune dysregulation may contribute to the pathogenesis of LIP. Differentiation from Sjögren's syndrome is needed in particular cases.
Lymphoid interstitial pneumonia is not a hereditary disease. However, host genetic factors and viral genetic elements influence susceptibility to the development of LIP.
HLA type: specific HLA alleles determine the strength of the EBV-related immune response. Alleles such as HLA-DR3 and HLA-DR52 increase the autoimmune tendency and may raise the risk of concurrent HIV-associated LIP and Sjögren-like syndrome. HLA-B*57:01 is associated with the EBV-specific CD8+ T-cell response and may influence EBV-related lung lesions.
CXCR4 and CCR5 polymorphisms: CXCR4 receptor polymorphisms modulate susceptibility to T-tropic HIV variants and influence pulmonary CD8+ T-cell migration. Carriers of the CCR5-Δ32 mutation have resistance to HIV infection itself, but once infected, qualitative differences in the immune response may influence the risk of LIP.
EBV viral genes: polymorphisms in the C-terminal activation domain of EBV LMP-1 affect proliferative capacity. EBV latency genes (EBNA-1, 2, LMP-1, -2A/-2B) are expressed in LIP lung tissue, and their expression pattern determines the clinical course of EBV-associated LIP. In addition, the higher the EBV genome copy number (viral load), the more active the lymphocyte proliferation.
Immunodeficiency-related genes: in HIV-infected children, inborn errors of immunity (e.g., STAT3 gain-of-function, PI3K activating mutations) can cause LIP-like pulmonary lymphoproliferation. This suggests the need to exclude underlying immunodeficiency when diagnosing HIV-associated LIP.
The epidemiologic characteristics of HIV-associated lymphoid interstitial pneumonia (LIP) differ markedly by age group and ART availability.
Pediatric prevalence: before the introduction of ART, LIP occurred in about 25–40% of HIV-infected children. In children, LIP was the most important pulmonary complication together with Pneumocystis pneumonia (PCP). After the introduction of ART, the incidence of pediatric LIP fell by more than 90% in high-income countries, but prevalence remains high in regions with limited ART access such as sub-Saharan Africa.
Adult prevalence: LIP is rare in HIV-infected adults, at 1–3% of the total. Adult LIP occurs mainly in the chronic stage of HIV infection (CD4+ T cells 200–500/μL) and is more common in the moderately immunosuppressed state than in the stage of severe immune depletion. This is interpreted as meaning that a certain degree of immune activity (lymphocyte proliferative capacity) is needed for the development of LIP.
Geographic distribution: LIP is most commonly reported in African children with HIV. In studies conducted in Zambia, Zimbabwe, and Tanzania, the cumulative incidence of LIP in HIV-infected children not treated with ART reached 30–50%. A significant incidence of LIP has also been reported in children with HIV in Southeast Asia.
Sex and age distribution: in children there is no sex difference in LIP. In adults, LIP accompanied by Sjögren-like symptoms is reported more commonly in women with HIV. The age at onset of LIP is most often 2–10 years in children, and in adults it occurs mainly in the chronic infection stage, several years after HIV infection.
The pathogenesis of HIV-associated lymphoid interstitial pneumonia is understood to center on local pulmonary immune abnormalities from HIV infection and the combined action of EBV.
Stage 1: abnormal pulmonary lymphocyte migration: systemic immune activation due to HIV infection increases expression of lymphocyte adhesion molecules (VCAM-1, ICAM-1) in the pulmonary vasculature. Activated CD8+ T lymphocytes and EBV-infected B lymphocytes flow into the lung parenchyma. CXCL13 secreted by alveolar macrophages amplifies B-lymphocyte migration.
Stage 2: accumulation of lymphocytes in the alveolar interstitium: the influxed lymphocytes extensively infiltrate the alveolar walls and the peribronchiolar areas. Histologically, uniform lymphocyte and plasma cell infiltration of the alveolar septa, germinal center formation, and lymphoid aggregates mixed with B and T cells are characteristic. Prolonged B-cell survival driven by EBV LMP-1 promotes B-cell accumulation.
Stage 3: impaired gas exchange: thickening of the alveolar interstitium increases the alveolar–capillary diffusion distance and decreases lung compliance. A restrictive ventilatory defect and decreased DLCO occur. Cyst formation (not uncommon in LIP) suggests destruction of lung architecture and raises the risk of pneumothorax.
Stage 4: ART response and IRIS: after ART initiation, the EBV-specific immune response is strengthened along with recovery of CD4+ T cells. This strengthens the immune attack on EBV-infected cells, and transient worsening of pulmonary inflammation (IRIS) may occur. However, in most cases LIP improves as the immune overactivation normalizes with continued ART.
The clinical symptoms of lymphoid interstitial pneumonia follow a slowly progressive chronic course, with some differences between children and adults.
Respiratory symptoms: chronic nonproductive cough is the most common symptom and worsens slowly over weeks to months. It begins with mild cough and dyspnea on exertion and progresses to dyspnea at rest. Fever occurs intermittently and is sometimes accompanied by night sweats.
Systemic symptoms: weight loss, fatigue, and generalized weakness accompany. In pediatric patients, growth retardation is prominent. In adult patients, generalized weakness from HIV infection overlaps with LIP symptoms, which can make initial distinction difficult.
Pediatric-specific symptoms: in pediatric HIV-associated LIP, parotid gland enlargement is characteristically observed. This is due to lymphocytic infiltration of the parotid gland and occurs almost simultaneously with LIP. Generalized lymphadenopathy accompanies, and hepatosplenomegaly is also common. Digital clubbing is a sign of chronic hypoxemia and is observed in children with advanced disease.
Decreased oxygen saturation: resting blood oxygen saturation (SpO₂) is initially normal, but hypoxemia appears first during exercise or sleep. In advanced cases, decreased resting SpO₂ (below 92%) and cyanosis occur. Severe hypoxemia can lead to pulmonary hypertension and cor pulmonale.
Imaging findings: on chest X-ray, interstitial nodular infiltrates with bilateral lower-lobe predominance are characteristic. The nodules are fine nodules 1–5 mm in size, distributed around the hila and in the lower lobes. High-resolution CT (HRCT) shows bilateral ground-glass opacity, nodules in a peribronchovascular distribution, centrilobular nodules, and cyst formation. Cysts are a characteristic finding of LIP, varying from 1 to 30 mm in diameter and located mainly in the lower lobes. Pleural effusion is uncommon.
Pulmonary function tests: a restrictive ventilatory defect (decreased lung volume, FVC↓, TLC↓) and decreased diffusing capacity for carbon monoxide (DLCO) are characteristic. An obstructive defect is generally absent, but a mixed pattern may be seen with peribronchial LIP infiltration. The 6-minute walk test confirms decreased oxygen saturation and reduced exercise tolerance.
Blood and immunological tests: the CD4+ T-cell count is often moderately reduced (100–400/μL) in HIV LIP. Quantitative HIV RNA (viral load) is positive. Elevated serum EBV antibodies (VCA IgG, EA IgG) and positive EBV DNA PCR. Hypergammaglobulinemia of serum immunoglobulins (IgG, IgA, IgM) is common. Antinuclear antibody (ANA) and rheumatoid factor are positive in some.
Bronchoalveolar lavage (BAL): BAL cell analysis characteristically shows lymphocytosis with CD8+ T-lymphocyte predominance. The CD4/CD8 ratio is inverted to below 0.3. EBV DNA PCR can be performed on BAL fluid.
Histopathology: definitive diagnosis is made by lung biopsy (transbronchial or surgical). Tissue findings: uniform lymphocyte and plasma cell infiltration of the alveolar septa, lymphoid follicles with germinal centers, clusters of plasma cells. If EBV EBER in situ hybridization is positive, it is confirmed as EBV-associated LIP. Differentiation from lymphoma is confirmed by clonality testing (immunoglobulin gene rearrangement).
Screening for HIV-associated lymphoid interstitial pneumonia should be carried out systematically in HIV-infected individuals with respiratory symptoms.
Clinical screening: at regular outpatient visits, all HIV-infected individuals are asked about respiratory symptoms (cough, dyspnea). In HIV-infected children, LIP-related signs such as parotid swelling, clubbing, and growth retardation are checked regularly. Resting SpO₂ is measured by pulse oximetry, and any drop in SpO₂ after exercise is checked.
Imaging screening: if there are respiratory symptoms or decreased SpO₂, chest X-ray is performed first. If bilateral interstitial infiltrates are seen on chest X-ray, HRCT is added to confirm the findings characteristic of LIP (nodules, ground-glass opacity, cysts). Especially in children with chest X-ray abnormalities together with parotid swelling, LIP is considered first.
Immunological screening: the risk of LIP is high in HIV-infected individuals with a CD4+ T-cell count in the range of 200–500/μL. EBV infection status is assessed by EBV serology (VCA IgG, EA IgG). Hypergammaglobulinemia is checked by measuring serum immunoglobulin levels.
Considering the differential diagnosis: in the screening process for LIP, Pneumocystis pneumonia (PCP), tuberculosis, Mycobacterium avium complex (MAC) infection, HIV-associated lung cancer, and lymphoma must be excluded at the same time. In particular, PCP takes priority when CD4 is <200/μL, and when chronic interstitial infiltrates are seen at CD4 ≥200/μL, a differential diagnosis including LIP is needed.
Definitive diagnosis of HIV-associated lymphoid interstitial pneumonia is made by synthesizing clinical, imaging, and histopathologic findings.
Clinical diagnostic criteria: (1) confirmed HIV infection, (2) respiratory symptoms (cough, dyspnea) persisting for 3 months or more, (3) bilateral interstitial infiltrates on chest X-ray/HRCT, (4) exclusion of other causes (infection, malignancy). In children, if these criteria are met, clinical diagnosis is possible without tissue biopsy (CDC 1987 criteria).
HRCT diagnosis: typical HRCT findings (bilateral ground-glass opacity, peribronchovascular nodules, cysts) have high diagnostic value. Cyst formation is a very specific finding for LIP. HRCT interpretation by a radiology specialist allows diagnosis in most cases.
Bronchoscopy and BAL: if cell analysis after bronchoalveolar lavage (BAL) shows CD8+ lymphocytosis, LIP is strongly suggested. A positive EBV DNA PCR in BAL provides additional evidence. Transbronchial lung biopsy (TBLB) has a low diagnostic yield, so surgical lung biopsy is preferred for final confirmation.
Surgical lung biopsy: lung tissue is obtained by video-assisted thoracoscopic surgery (VATS) or open biopsy for histologic confirmation. Tissue findings: uniform lymphocyte and plasma cell infiltration of alveolar septa, germinal center formation, positive EBV EBER in situ hybridization. Differentiate from lymphoma by clonality testing.
Differentiation from lymphoma: differentiation of LIP from MALT (mucosa-associated lymphoid tissue) lymphoma is very important. Clonal proliferation is assessed by immunohistochemical staining (κ to λ light chain ratio) and immunoglobulin gene rearrangement (PCR or Southern blot). If clonal proliferation is present, lymphoma is diagnosed.
Treatment of HIV-associated lymphoid interstitial pneumonia is based on treatment of HIV infection itself (ART), with additional treatment applied according to symptom severity.
Antiretroviral therapy (ART): early initiation of ART is the key to prevention and treatment of LIP. ART is started immediately regardless of the CD4+ T-cell count. HIV RNA suppression and CD4 recovery by ART normalize the pulmonary immune environment and improve LIP. In most mild LIP, imaging findings and symptoms improve within 6–12 months with ART alone.
Corticosteroids: prednisolone is used when there is resting hypoxemia (PaO₂ <60 mmHg or SpO₂ <90%). Adult initial dose: prednisolone 1 mg/kg/day (maximum 40–60 mg/day) for 4–8 weeks, then gradual tapering. Children: start at 1–2 mg/kg/day and adjust according to clinical response. PCP prophylaxis (TMP-SMX or atovaquone) is essential when using steroids.
IRIS management: worsening of LIP (IRIS) may occur within 4–8 weeks after ART initiation. Mild IRIS is managed with continued ART and symptomatic treatment. Severe IRIS (severe hypoxemia, rapid deterioration of pulmonary function) is treated with prednisolone 1 mg/kg/day for 2–4 weeks. As a principle, ART is not discontinued.
Oxygen therapy and supportive care: long-term oxygen therapy is needed in patients with chronic hypoxemia. Pulmonary rehabilitation (breathing exercises, aerobic exercise) improves exercise tolerance. If pneumothorax occurs, consider chest tube insertion and pleurodesis.
EBV-specific treatment: currently, EBV-specific antivirals (ganciclovir, acyclovir) are not effective against latent EBV infection. Therefore anti-EBV treatment is not recommended in EBV-associated LIP, and the focus is on ART and steroid treatment.
The prognosis of HIV-associated lymphoid interstitial pneumonia has improved overall since the introduction of ART, but varies according to stage at diagnosis and treatment adherence.
ART response: in about 70–80% of patients who respond to ART (achieving HIV RNA suppression), LIP imaging findings and pulmonary function improve. Partial or complete resolution of imaging findings is observed with recovery of the CD4+ T-cell count (>200/μL). In some patients cysts remain on HRCT, but symptoms resolve.
Pediatric prognosis: five-year survival of HIV-infected children not treated with ART is about 60–75% after the diagnosis of LIP. In children treated with ART, the prognosis improves considerably, with five-year survival reported at 85% or higher. Parotid swelling and clubbing resolve slowly after ART.
Complications: spontaneous pneumothorax due to cyst formation occurs in about 5–10%. Recurrent pneumothorax requires pleurodesis or thoracoscopic surgery. The prognosis is poor if pulmonary hypertension develops. Rarely, LIP can progress to low-grade MALT lymphoma (2–5%).
Adult prognosis: HIV-associated LIP in adults responds well to ART, and with appropriate treatment the long-term prognosis is good. However, refractoriness to ART or poor adherence can lead to progressive pulmonary fibrosis. The lower the baseline CD4 count, the higher the risk of LIP progression.
Early HIV diagnosis and ART: early diagnosis of HIV infection and immediate ART initiation are the most effective ways to prevent LIP. If HIV RNA remains suppressed, the risk of LIP falls by more than 90%. Blocking neonatal HIV infection through prevention of mother-to-child transmission (PMTCT) programs is fundamental to preventing pediatric LIP.
Management of EBV infection: EBV infection status is determined by EBV serology in HIV-infected individuals, and signs of EBV reactivation (parotid swelling, lymphadenopathy) are detected early. An EBV preventive vaccine is currently at the clinical trial stage, but immune recovery is the most realistic strategy to suppress EBV reactivation in HIV-infected individuals.
Regular monitoring: in both HIV-infected children and adults, asymptomatic LIP is detected early by regular chest X-ray and pulmonary function tests. Active pulmonary monitoring is needed especially in children with parotid swelling or clubbing. Regular pulse oximetry allows early detection of asymptomatic hypoxemia.
Maintaining immune status: improving ART adherence to maintain a CD4+ T-cell count of 200/μL or above is important for preventing LIP. Immune status is assessed and ART optimized through regular HIV monitoring (CD4 count, viral load).